TABLE 1.
General baseline characteristics of patients
| Characteristic | No. of patients (n = 303) | Percentage (%) |
|---|---|---|
| Gender | ||
| Male | 189 | 62.4% |
| Female | 114 | 37.6% |
| Age | ||
| Median (range) | 63 (23–88) | |
| Histological type | ||
| Adenocarcinoma | 274 | 90.4% |
| Squamous carcinoma | 13 | 4.3% |
| Adenosquamous carcinoma | 1 | 0.3% |
| SCLC | 4 | 1.3% |
| Others a | 11 | 3.6% |
| Clinical stage | ||
| III | 63 | 20.8% |
| IV | 240 | 79.2% |
| Oncogenic types | ||
| EGFR | 130 | 42.9% |
| TP53 | 159 | 52.5% |
| ALK | 30 | 9.9% |
| MET | 21 | 6.9% |
| KRAS | 36 | 11.9% |
| ROS1 | 11 | 3.6% |
| BRAF | 12 | 4.0% |
| ERBB2 | 16 | 5.3% |
| RET | 11 | 3.6% |
| NSE | ||
| Elevated | 209 | 69.0% |
| Normal | 94 | 31.0% |
| CEA | ||
| Elevated | 197 | 65.0% |
| Normal | 106 | 35.0% |
| CA125 | ||
| Elevated | 172 | 56.8% |
| Normal | 131 | 43.2% |
| CA153 | ||
| Elevated | 140 | 46.2% |
| Normal | 163 | 53.8% |
| CYFRA21‐1 | ||
| Elevated | 236 | 77.9% |
| Normal | 67 | 22.1% |
| SCC | ||
| Elevated | 102 | 33.7% |
| Normal | 201 | 66.3% |
a
Others include epitheliomatoid carcinoma, complex small cell carcinoma, and other unknown pathological types of lung cancer.